Clinical trial
GM-CSF as Adjuvant Therapy of Melanoma
NCT00350597 · Northern California Melanoma Center, Other · Completed
Key facts
| NCT number | NCT00350597 |
|---|---|
| Title | GM-CSF as Adjuvant Therapy of Melanoma |
| Official title | Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma. |
| Lead sponsor | Northern California Melanoma Center, Other |
| Collaborators | Bayer Industry Melanoma Research Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) |
| Enrollment | 50 |
| Start date | Sep 1, 2004 |
| Completion | Jul 1, 2010 |
| First posted | Jul 11, 2006 |
| Last update posted | Jul 11, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: